Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25905688 | 0.83 | CYP2D6 (0.33) | HRH3CYP2D6 | |
| SCHEMBL23324538 | 0.80 | MMP9 (0.32) | HRH3CYP2D6 | |
| SCHEMBL25912714 | 0.76 | DPP4 (0.33) | OPRM1 | |
| SCHEMBL25932195 | 0.75 | OPRM1 (0.32) | OPRM1 | |
| SCHEMBL25932854 | 0.74 | HRH3 (0.35) | HRH3CYP2D6 | |
| SCHEMBL23323492 | 0.73 | USP30 (0.31) | — | |
| SCHEMBL25953110 | 0.73 | HRH3 (0.30) | HRH3 | |
| SCHEMBL12026459 | 0.72 | L3MBTL1 (0.40) | OPRM1KDM4EALDH1A1L3MBTL1 | |
| SCHEMBL22198690 | 0.72 | KMT2A (0.36) | HRH3 | |
| SCHEMBL23324599 | 0.72 | CTSS (0.31) | OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230233569-A1 | METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2023-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230233569-A1 | METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS | KRAS, HRAS, MTOR | HRH3 3890/4885OPRM1 4485/4885CYP2D6 4714/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.